Medical Devices Market Research Reports And Industry Analysis

Our coverage in Medical Devices category covers medical disposable utilities, to coronary drug eluting stents, from medical beds to magnetic resonance imaging systems, from small firms, niche players to large multinational corporations. It covers devices and equipments required in diagnostics, pharmaceuticals and health care sectors.

Research Announces Pharmaceutical Market - Brazil, United Kingdom and Russia Report At Researchmoz.us

Wednesday, 19 March 2014

Researchmoz presents this most up-to-date research on"Research Announces Pharmaceutical Market - Brazil, United Kingdom and Russia Report At Researchmoz.us". The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.


The Brazilian pharmaceutical market remains our favourite regional market in Latin America due to its large market size and strong domestic demand for innovative, high-tech products. The government i s increasing ly invest ing in the healthcare sector and pharmaceutical industry to reduce the financial burden of diseases , and the country's private healthcare sectors provide opportunities for foreign companies. However, the increasing d rug rebate level has significantly undermined the profits recorded by generic drugmakers. The more aggressive government techonology transfer deals with multinationals as well as the drug approval delays due to bureaucracy and staff shortages at ANVISA have also dampened multinationals' revenue-generating opportunities.The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.


Drugmakers and governments will increasingly enter agreements that provide some form of risk- sharing or price protection for new drugs. Since most European governments, including the UK authorities, are focussing on cost containment in the healthcare sector, alternative pricing schemes for medicines allow for budget control, as well as providing patients with access to highly innovative treatments. Guidance drafted by the National Institute for Health and Clinical Excellence (NICE) has recommended the use of Bristol-Myers Squibb 's Yervoy (ipilimumab) and Roche's Zelboraf ( vemurafenib) for the treatment of advanced skin cancer. These are the first new drugs approved for routine use by the UK's National Health Service for the disease in more than a decade. While this is positive news for both drugmakers, NICE's stamp of approval came only after the manufacturers of both drugs agreed to offer discounts, overturning a prior rejection of the treatments by the watchdog.The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.Pharmaceuticals: GBP23.81bn (US$38.33bn) in 2011 to GBP23.74bn (US$37.27bn) in 2012; -0.3% in local currency terms and -2.8% in US dollar terms. Forecast unchanged from Q4 12.Healthcare: GBP144.79bn (US$232.99bn) in 2011 to GBP149.35bn (US$234.48bn) in 2012; +3.2% in local currency terms and +0.6% in US dollar terms. Forecast unchanged from Q4 12.Medical devices: GBP5.89bn (US$9.48nn) in 2011 to GBP5.93bn (US$9.30bn) in 2012; +0.6% in local currency terms and -1.9% in US dollar terms. Forecast unchanged from Q4 12.


The Russian pharmaceutical market remains a powerhouse in the Emerging Europe region . The country has by far the larg est population in the region. I ts resource s -driven economic growth is funding both private and public spending on medicines and healthcare services. The country's World Trade Organisation (WTO) accession has eliminated tariff barriers and should, in the long run, drive major improvements in a problematic intellectual property environment.Both domestic and cross-border mergers and acquisitions (M&A) activity has picked up since the 2009 economic crisis, a result of increased incentives for local production under the government's industrial policy for the sector and the need for scale to compete , especially in the generic medicines market. We believe a critical forward step for the market will be the successful implementation of a broad-based medicines insurance programme in the next few years, following current pilot projects. If this proves successful, we would expect growth to outstrip our current five-year projection for a compound annual growth rate of 8.3% in US dollar terms during the period 2012-2017.The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

For More Information Kindly Contact:
Email: sales@researchmoz.us
Web Site: http://www.researchmoz.us/
word press : http://marketresearchtopix.wordpress.com

0 comments:

Post a Comment